Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W David Henner

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Oncotarget|February 29, 2012
A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancersAnita Lal, Rebecca Panos, Mira Marjanovic, et al.
Diagnostic Pathology|March 19, 2013
A gene expression profile test to resolve head & neck squamous versus lung squamous cancersAnita Lal, Rebecca Panos, Mira Marjanovic, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer, Anne Myrthue, Mark Garzotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of originFederico A Monzon, Maureen Lyons-Weiler, Ljubomir J Buturovic, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2006
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer, Milind M Javle, Christopher W Ryan, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Journal of Surgical Oncology|April 12, 2011
Unique patterns of metastases in common and rare types of malignancyStanley P L Leong, Eric K Nakakura, Raphael Pollock, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancerRandall P Rago, Albert Einstein, Richard Lush, et al.
The American Journal of Surgical Pathology|May 8, 2013
A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumorsCharles R Handorf, Anand Kulkarni, James P Grenert, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Oncotarget|February 29, 2012
A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancersAnita Lal, Rebecca Panos, Mira Marjanovic, et al.
Diagnostic Pathology|March 19, 2013
A gene expression profile test to resolve head & neck squamous versus lung squamous cancersAnita Lal, Rebecca Panos, Mira Marjanovic, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomyTomasz M Beer, Anne Myrthue, Mark Garzotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of originFederico A Monzon, Maureen Lyons-Weiler, Ljubomir J Buturovic, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2006
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer, Milind M Javle, Christopher W Ryan, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Journal of Surgical Oncology|April 12, 2011
Unique patterns of metastases in common and rare types of malignancyStanley P L Leong, Eric K Nakakura, Raphael Pollock, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancerRandall P Rago, Albert Einstein, Richard Lush, et al.
The American Journal of Surgical Pathology|May 8, 2013
A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumorsCharles R Handorf, Anand Kulkarni, James P Grenert, et al.
Pageof 3